XML 40 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended
Jul. 31, 2012
Jul. 31, 2011
Operating revenue:    
Personalized oncology solutions $ 918 $ 601
Translational oncology solutions 1,188 1,033
Total operating revenue 2,106 1,634
Costs and operating expenses:    
Cost of personalized oncology solutions 772 483
Cost of translational oncology solutions 699 419
Research and development 387 541
Sales and marketing 709 688
General and administrative 1,138 1,717
Total costs and operating expenses 3,705 3,848
Loss from operations (1,599) (2,214)
Other income (expense):    
Change in fair value of warrant liability 285 177
Other expense (6) 0
Total other income 279 177
Loss before provision for income taxes (1,320) (2,037)
Provision for income taxes 3 0
Net loss $ (1,323) $ (2,037)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share) $ (0.03) $ (0.04)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares) 47,067,000 46,420,000